PP2A-Mediated Autophagy Drives Drug Resistance in Candida albicans Biofilms

Study Background and Research Question

Candida albicans is a prominent opportunistic fungal pathogen, notorious for its ability to form robust biofilms on mucosal surfaces and medical devices. These biofilms exhibit inherent resistance to major antifungal agents, including azoles such as Fluconazole, which acts by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase—a central step in ergosterol biosynthesis (internal_article). The growing clinical challenge posed by drug-resistant C. albicans biofilms necessitates a deeper understanding of the mechanisms underpinning both biofilm formation and resistance emergence. Autophagy, a vital cellular process for adaptation to stress and nutrient deprivation, has been implicated in fungal pathogenicity and drug response, but its precise regulatory role in biofilm-associated drug resistance remained unclear.

Key Innovation from the Reference Study

The study by Shen et al. (DOI:10.1016/j.identj.2025.103873) provides the first systematic evidence that protein phosphatase 2A (PP2A), specifically via its catalytic subunit encoded by PPH21, modulates drug resistance in C. albicans biofilms through the induction of autophagy and phosphorylation of ATG proteins. By genetically disrupting PPH21 and pharmacologically activating autophagy, the authors delineate a mechanistic axis linking PP2A activity, autophagy signaling, and antifungal susceptibility.

Methods and Experimental Design Insights

The investigators constructed a pph21Δ/Δ mutant strain to assess the role of PP2A in autophagy and biofilm physiology. Biofilm formation and drug susceptibility were evaluated under conditions of autophagy activation (using rapamycin) and inhibition. Multiple assays were employed:

• Gene and protein expression: Quantification of PPH21, Atg13, and Atg1 levels to track autophagy pathway activation.
• Biofilm quantification: Standard colorimetric and microscopic methods to assess biomass and structure.
• Antifungal susceptibility testing: Determination of drug sensitivity profiles for both wild-type and mutant strains, using established in vitro and in vivo models.
• Oxidative stress assays: Measurement of reactive oxygen species to evaluate stress adaptation.
• In vivo infection model: Oral candidiasis in mice, assessing the efficacy of antifungal therapy in the context of genetic and pharmacological manipulation of autophagy.

Protocol Parameters

• assay | Fluconazole minimum inhibitory concentration (IC₅₀) | 0.5–10 μg/mL | In vitro antifungal susceptibility testing for various C. albicans strains | Defines drug efficacy baseline for resistance assessment | product_spec
• assay | Fluconazole working concentration | 10 μg/mL | Cell-based biofilm inhibition and resistance modeling | Enables reproducible comparison with literature protocols | product_spec
• assay | Fluconazole intraperitoneal dosing | 80 mg/kg/day | Mouse oral candidiasis infection model | Supports in vivo evaluation of antifungal efficacy | product_spec
• assay | DMSO solubility | ≥10.9 mg/mL | Stock preparation for in vitro assays | Ensures accurate dosing and solution stability | product_spec
• assay | Rapamycin treatment | literature-optimized range | Autophagy activation in C. albicans biofilm experiments | Induces autophagy to probe resistance mechanisms | workflow_recommendation

Core Findings and Why They Matter

The study's pivotal discoveries include:

• The PPH21 gene is positively correlated with biofilm formation and antifungal drug resistance in C. albicans (reference_paper).
• Disruption of PPH21 (in pph21Δ/Δ mutants) results in impaired autophagy—evidenced by reduced levels of phosphorylated Atg13 and Atg1 proteins—and attenuates both biofilm development and drug resistance.
• Pharmacological activation of autophagy with rapamycin enhances biofilm robustness and drug resistance in wild-type strains, but not in pph21Δ/Δ mutants, underscoring the requirement for PP2A in this regulatory pathway.
• In vivo, autophagy activation diminishes the therapeutic efficacy of antifungal agents in the mouse oral infection model, whereas pph21Δ/Δ mutants remain susceptible to treatment, indicating a loss of drug tolerance mechanisms.

These findings establish PP2A-mediated autophagy as a central driver of biofilm-associated antifungal resistance. The mechanistic insight that ATG protein phosphorylation, under PP2A control, is essential for this adaptive resistance, opens up potential intervention points for improving the efficacy of ergosterol biosynthesis inhibitors and related agents.

Comparison with Existing Internal Articles

Several internal resources have previously explored the landscape of antifungal drug resistance and the use of triazole-based agents such as Fluconazole. For example, the article "Fluconazole and Fungal Drug Resistance: Mechanisms, Models, and New Insights" provides a comprehensive overview of resistance mechanisms—highlighting the significance of autophagy, efflux pump regulation, and biofilm structure. However, the current reference study uniquely identifies PP2A as a critical upstream regulator of autophagy-dependent resistance, specifically via ATG protein phosphorylation. This mechanistic link was previously hypothesized but not directly demonstrated in the context of biofilm-mediated resistance.

Moreover, "Fluconazole: Atomic Facts for Antifungal Susceptibility &..." and "Fluconazole: Antifungal Mechanism, Evidence, and Research..." reinforce that Fluconazole’s activity as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor is both strain- and context-dependent, especially in the presence of biofilm-associated resistance mechanisms. The present study adds granularity by linking this context-dependence to autophagy pathway status, suggesting that targeting PP2A or autophagy regulators could enhance the utility of existing antifungal agents.

Limitations and Transferability

While the study provides compelling genetic and pharmacological evidence for PP2A’s role in autophagy-mediated drug resistance, some limitations warrant consideration:

• Most experiments were performed using a single clinical laboratory strain and selected mutants; broader screening across diverse clinical isolates will be necessary to generalize findings.
• Although mouse oral infection models recapitulate human-relevant features of biofilm-associated candidiasis, interspecies differences may influence the observed autophagy-drug resistance dynamics.
• The study focused on rapamycin as a canonical autophagy activator; future work could investigate other modulators and their combinatory effects with ergosterol biosynthesis inhibitors.

Nonetheless, the mechanistic insight is highly relevant for the design of improved antifungal susceptibility testing and for developing next-generation strategies aimed at overcoming biofilm-related drug resistance in C. albicans (internal_article).

Research Support Resources

Researchers aiming to reproduce or extend these findings can employ validated antifungal agents such as Fluconazole (SKU B2094), a triazole-based fungal cytochrome P450 enzyme 14α-demethylase inhibitor, for in vitro and in vivo resistance modeling and biofilm studies (source: workflow_recommendation). APExBIO’s reagent is formulated for consistent antifungal susceptibility testing, Candida albicans infection model development, and mechanistic exploration of drug resistance and ergosterol biosynthesis inhibition. For best results, refer to literature protocols and product specifications for assay design and solution preparation. This resource is intended for scientific research use only.